Esteve invests €100 million in new manufacturing plant in Spain
.png)
Esteve team. Source: [1]
Spain-headquartered CMO Esteve expands its manufacutring capacity in plants in Girona, Spain to increase global API offerings with advanced technological solutions, through a weighty investment of €100 million.
Esteve is a leading healthcare company and pharmaceutical innovator and partner based in Spain.
Esteve has a global presence, mostly throughout Europe, but with industrial sites in China and Mexico. In Spain, Esteve has a chemical R&D centre in Barcelona, and three production plants in the Catalan region, located in Celrà (Gironès), Banyeres del Penedès (Baix Penedès), and Lliçà de Vall (Vallès Oriental). Now, they have plans to further increase manufacturing capacity in the region.
Esteve has initiated a project to construct a new manufacturing unit at its Celrà plant in Girona, with plans to invest €100 million through to 2026. The expansion aims to boost the production capacity of active pharmaceutical ingredients at its primary industrial site. Once the new facilities become operational in the latter quarter of 2026, the company will welcome approximately 100 new employees to its existing team of 370 professionals. The expansion includes building new production and service facilities and installing up to 150 m3 of reaction volume, leading to a 45% increase in Esteve's production capacity at Celrà and a 15% increase in the overall global capacity of the company.
The new unit in Girona illustrates the dedication to advancements in developing, manufacturing, and sales of APIs for CMOs. The latest technological solutions, including in digitalisation and data analysis, incorporated into the facility will ensure the efficient production of highly-potent APIs.
The facility enables the production of new products to be added to Esteve’s portfolio, which will be distributed throughout the USA, Europe, and Japan.
"Thanks to our commitment to quality, efficiency and reliability, our activity in the development and manufacturing of active pharmaceutical ingredients has experienced notable growth in recent years. The expansion of our main industrial centre will allow us to satisfy a growing global demand and expand our activity, advancing our mission of improving people's lives", commented Pere Mañé, the General Manager of Esteve Química.
Source:
[1] Esteve Química. Esteve will invest 100 million euros in the construction of a new plant at its industrial centre in Celrà (Girona). [Date accessed 09/07/2024] www.esteve.com/global/news/esteve-will-invest-100-million-euros-in-the-construction-of-a-new-plant-at-its-industrial-centre-in-celra-girona
Related News
-
News A Day in the Life of Oncology Start-Up Co-Founder & CEO
This Women's month we are highlighting stories of women in the pharma industry (building on what we do every month to support women), so for the Day in the Life of we are speaking to Sharon Cunningham who is the Co-founder and CEO of Shorla On... -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News A Day in the Life of a Head of Market Insights in med devices
The latest interview in the Day in the Life of Series is with Alper Hulusi, Head of Market Insights for ClariMed. Hulusi also works to try to get to know people, this time from the other side of pharma – the people that will be using the the... -
News CPHI Podcast Series: Packaging expert perspectives at Pharmapack 2025
This month's podcast episode sounds a little different, covering the latest event in Paris – Pharmapack 2025. Digital Editor Lucy Chard speaks to several experts direct from the floor of the show, bringing you right in on the action.&nbs... -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News The 2025 Pharmapack Awards: recognising innovation and patient centricity
This year in Paris the Pharmapack Awards recognised the achievements across categories in the industry, aswell as including some new categories to highlight exceptional work and people. -
News Pharmapack 2025: From the Floor in Paris
Pharmpack gears up for another week in Paris at the Porte De Versailles. The two-day show taking place on the 22–23 January, will cover contract packaging, device innovation, and sustainability among other topics. -
News Visibility, Integration, and Opportunity with CPOs: A Pharmapack Interview
At Pharmapack 2025 in Paris the informative content tracks this year will feature a Contract Packaging track. A critically important topic for those working in the field, which speaker Alexander Schäfer from Sharp Services discusses in the fo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance